Targets › AQP1
2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Gastroenterology, Oncology; next expected readout Jun 2027.
Forms a water channel that facilitates the transport of water across cell membranes, playing a crucial role in water homeostasis in various tissues. Could also be permeable to small solutes including hydrogen peroxide, glycerol and gases such as amonnia (NH3), nitric oxide (NO) and carbon dioxide (CO2). (UniProt, P29972)
Open in Phaseline: the race on AQP1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| MeiraGTx | AAV2-hAQP1 AAV2-delivered aquaporin-1 gene therapy | AQP1 | Phase 2 | Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands | Jun 2027 |
| RiboX Therapeutics | RXRG001 Circular RNA encoding human aquaporin 1 delivered via lipid nanoparticle | AQP1 | Phase 1 | Radiation-Induced Xerostomia and Hyposalivation | Aug 2027 |
Radiation-Induced Xerostomia and Hyposalivation (1) Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands (1)
protein or peptide (1), other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.